EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-Metaanalyse

Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: Systematic review and network meta-analysis

Yaxuan Zheng, Yue Han, Jincong Chen, Jiahao Huang, Changhua Zhu, Lihang Lin, Huichun Su

Indian Journal of Dermatology, Venereology and Leprology · 2024

DOI: 10.25259/ijdvl_775_2023 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Indian Journal of Dermatology, Venereology and Leprology, 2024. Verfasst von Yaxuan Zheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venerology, Fujian Medical University Union Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Psoriasis, Severity of Illness Index, TYK2 Kinase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Janus kinase (JAK)/tyrosine kinase 2 (TYK2) inhibitors are novel treatments for moderate-to-severe plaque psoriasis.

Objective

To perform a network meta-analysis to compare the efficacy and safety of TYK2 inhibitors with other oral drugs in moderate-to-severe psoriasis.

Methods

Eligible randomised clinical trials (RCTs) were identified from public databases (published before November 2, 2023). Random-effect frequentist network meta-analysis was performed with ranking based on the surface under the cumulative ranking curve (SUCRA) of Physician’s Global Assessment of “clear” or “almost clear” (PGA 0/1), 75% reduction from baseline in Psoriasis Area and Severity Index (PASI-75).

Results

Twenty RCTs containing 7,564 patients with moderate-to-severe psoriasis were included. Deucravacitinib at all dose levels (except for 3 mg every other day) and tofacitinib (10 mg BID) ranked best in achieving PGA 0/1 and PASI-75 at 12– 16 weeks. Tofacitinib (10 mg BID) was considered the most unsafe. Analysis of Ranking according to efficacy and safety showed deucravacitinib (3 mg QD and 3 mg BID) was the best treatment. Analysis of Ranking according to efficacy and safety showed deucravacitinib (3 mg QD and 3 mg BID) was the best treatment. Limitation Insufficiency of eligible data and no long-term follow-up data.

Conclusion

Deucravacitinib showed superior efficacy and safety for treating moderate-to-severe psoriasis over other included drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsPsoriasisSeverity of Illness IndexTYK2 KinaseTyrosine Kinase InhibitorsHumansAdministration, OralPiperidinesPyrimidinesRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

JAK inhibitorsTYK2biologicsdeucravacitinibpsoriasistofacitinib.

Substanzen

Janus Kinase InhibitorsPiperidinesPyrimidinestofacitinibTYK2 KinaseTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology and Venerology, Fujian Medical University Union Hospital, Fuzhou, China.

Zitieren

APA

Zheng, Y., Han, Y., Chen, J., Huang, J., Zhu, C., Lin, L., & Su, H. (2024). Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: Systematic review and network meta-analysis. Indian Journal of Dermatology, Venereology and Leprology. https://doi.org/10.25259/ijdvl_775_2023

Vancouver

Zheng Y, Han Y, Chen J, Huang J, Zhu C, Lin L, et al. Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: Systematic review and network meta-analysis. Indian Journal of Dermatology, Venereology and Leprology. 2024. doi:10.25259/ijdvl_775_2023

BibTeX
@article{Zheng2024,
  author = {Zheng, Yaxuan and Han, Yue and Chen, Jincong and Huang, Jiahao and Zhu, Changhua and Lin, Lihang and Su, Huichun},
  title = {Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: Systematic review and network meta-analysis},
  journal = {Indian Journal of Dermatology, Venereology and Leprology},
  year = {2024},
  doi = {10.25259/ijdvl_775_2023}
}
Kostenlos starten →